EV Therapeutics


EV Therapeutics is a pre-clinical staged neoantigen-based therapeutic cancer vaccine start-up focused on unlocking the full potential of the immune system to recognize and attack cancer by inducing an anti-tumor immune response in resistant "cold" tumors. Our platform technology is based on our proprietary nano-particle-sized engineered extracellular vesicles (mTEVs) that enhance T cell infiltration into the tumor microenvironment and synergize with immune checkpoint inhibitors (e.g. anti-PD-1, anti-PDL-1, anti-CTLA-4). Mechanistically, our platform activates T cell costimulation in the CD28/CD80 pathway, which is critical for a functioning immune system. Eight years of pre-clinical data show that treatment with our mTEVs significantly improves survival in late-stage disease models. Our findings potentially translate to a significant survival advantage for colorectal and pancreatic cancer patients with advanced disease or other gastrointestinal cancers. As a monotherapy, mTEVs prevent recurrence in high-risk Lynch syndrome patients by functioning as a prophylactic cancer vaccine.